Evidence map›Paper›PMID 26266104›Full record

ArticleWorld journal of clinical oncology2015

Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis.

Brigitta Badiani, Dario Maratea, Andrea Messori

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Brigitta BadianiBrigitta Badiani, Dario Maratea, Andrea Messori, HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy.
Dario MarateaBrigitta Badiani, Dario Maratea, Andrea Messori, HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy.
Andrea MessoriBrigitta Badiani, Dario Maratea, Andrea Messori, HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy.
Agenzia Regionale di Sanità della Toscana · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study the effectiveness of second-line treatments for advancer gastric cancer by application of Bayesian network meta-analysis.

methodsOur search covered the literature up to February 2015. The following 6 treatments were evaluated: (1) irinotecan (camptothecins); (2) paclitaxel (taxanes class); (3) docetaxel (taxanes); (4) everolimus (mammalian target of rapamycin inhibitors); (5) ramucirumab (vascular endothelial growth factor receptor 2 inhibitors); (6) ramucirumab + paclitaxel. Our methodology was based on standard models of Bayesian network meta-analysis. The reference treatment was best supportive care (BSC). The end-point was overall survival. Median survival was the outcome measure along with 95% credible intervals.

resultsOur search identified a total of 7 randomized controlled trials. These trials included 2298 patients (in 15 treatment arms) in whom a total of 6 active treatments were evaluated as well as BSC. There were 21 head-to-head comparisons (6 direct, 15 indirect). The difference in survival between each of two active treatments (paclitaxel and ramucirumab + paclitaxel) vs BSC was statistically significant, while the other 4 showed no statistical difference. In the 6 head-to-head comparisons between active treatments, no significant survival difference was demonstrated.

conclusionOur results indicate that both paclitaxel monotherapy and ramucirumab + paclitaxel determine a significant prolongation in survival as compared with BSC.

Indexed as

Advancer gastric cancerBayesian methodsDocetaxelIrinotecanMeta-analysisPaclitaxelRamucirumabSecond line therapy

Identifiers

PMID26266104
PMCPMC4530381
OpenAlexW1591198282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.